Series A AI companies in New York

Remepy is Pioneering Hybrid DrugsTM. Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. Remepy’s Digital MoleculesTM are designed to be the software apps within Hybrid DrugsTM. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. The Digital MoleculesTM enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptomsRemepy partners with pharma companies to bring Hybrid DrugsTM to market that will combine Remepy’s Digital MoleculeTM and traditional drug components.

• Series A
• 85 employees
• Founded 2022

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.

• Series A
• 51 employees
• Founded 2021

Accelerating scientific research and discoveries through the automation of histology and digital pathology solutions.Enhancing the human condition is what fuels our passion. Our services empower life science companies and researchers to introduce impactful breakthroughs and therapies to market with greater speed and precision than ever before. Our leading capabilities across histology, immunostaining, slide archiving/digitization services, pathology consultation, and image analysis consultation enable our customers to concentrate on the key questions to accelerate the processes of discovery, development, and delivery.We are much more than your average histology service provider. Our laboratory information system, PathologyMapTM, hosts one of the largest collections of preclinical data in the world and allows researchers the ability to instantly view, manage, and share their digital slides in seconds.HistoWiz emerged in 2013 as a valuable resource for scientific researchers seeking faster turnaround times than traditional histology cores could offer. This dedication to providing rapid results remains a cornerstone of our service, prompting customers to return to us time and time again.Quality first.Quality is behind everything that we do. From receiving your slides, to the quality of our images, through to our consultation teams, we adhere to the highest standards of quality and compliance.We support both GLP and non-GLP studies of all types and sizes. Our quality management system for GLP ensures FDA and EPA regulatory adherence.

• Series A
• 47 employees
• Founded 2012

Deeptune builds training gyms for AI agents.We want to work with people who share our core values:- Your work is a craft you want to master.- You thrive in ambiguity and approach new challenges with optimism.- You appreciate diverse perspectives and uncommon ideas.

• Series A
• 42 employees
• Founded 2022

Nilo Therapeutics is an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases. Our experienced team brings together diverse interdisciplinary expertise to modulate immune responses via activation of neural circuits. United by our passion for discovering and translating novel biology, we are dedicated to advancing human health through transformative science.

• Series A
• 37 employees
• Founded 2024